These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 21396519)

  • 1. [Long-term psoriasis treatment].
    Jullien D; Battistella M
    Ann Dermatol Venereol; 2011 Feb; 138(2 Suppl 1):H15-8. PubMed ID: 21396519
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety of anti-TNFα agents in the treatment of psoriasis and psoriatic arthritis.
    Girolomoni G; Altomare G; Ayala F; Berardesca E; Calzavara-Pinton P; Chimenti S; Peserico A; Puglisi Guerra A; Vena GA
    Immunopharmacol Immunotoxicol; 2012 Aug; 34(4):548-60. PubMed ID: 22296031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infections associated with the use of tumor necrosis factor-α inhibitors in psoriasis.
    Tan X; Balkrishnan R; Feldman SR
    J Drugs Dermatol; 2013 Mar; 12(3):e41-5. PubMed ID: 23545925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advertisements for TNF Inhibitors.
    Med Lett Drugs Ther; 2008 Nov; 50(1299):89. PubMed ID: 19008788
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy and safety of tumor necrosis factor inhibitors in acute generalized pustular psoriasis.
    Viguier M; Aubin F; Delaporte E; Pagès C; Paul C; Beylot-Barry M; Goujon C; Rybojad M; Bachelez H;
    Arch Dermatol; 2012 Dec; 148(12):1423-5. PubMed ID: 23247492
    [No Abstract]   [Full Text] [Related]  

  • 6. [What is the impact of the new clinical trial data? What are the lessons for patient management?].
    Passeron T; Boulinguez S
    Ann Dermatol Venereol; 2010 May; 137(5 Suppl 1):11-5. PubMed ID: 20510174
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of spondyloarthritides with anti-TNFalpha biologic agents.
    Braun J
    Reumatismo; 2006; 58 Spec No.1():71-2. PubMed ID: 23631067
    [No Abstract]   [Full Text] [Related]  

  • 8. Is there a benefit from using a subsequent anti-TNF α medication in psoriasis patients who failed their first or second anti-TNF α agent?
    Alsharqi A; Parslew R; Dever B; Arslanian V
    Australas J Dermatol; 2012 May; 53(2):e45-7. PubMed ID: 22571585
    [No Abstract]   [Full Text] [Related]  

  • 9. Anti-TNF agents for the treatment of psoriasis.
    Kircik LH; Del Rosso JQ
    J Drugs Dermatol; 2009 Jun; 8(6):546-59. PubMed ID: 19537380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nodular melanoma arising in a patient treated with anti-tumor necrosis factor alpha antagonists.
    Carlesimo M; La Pietra M; Arcese A; Di Russo PP; Mari E; Gamba A; Orsini D; Camplone G
    Int J Dermatol; 2012 Oct; 51(10):1234-6. PubMed ID: 22416995
    [No Abstract]   [Full Text] [Related]  

  • 11. Lack of anti-drug antibodies in patients with psoriasis well-controlled on long-term treatment with tumour necrosis factor inhibitors.
    Meyer MW; Zachariae C; Bendtzen K; Skov L
    Acta Derm Venereol; 2012 Jul; 92(4):362-4. PubMed ID: 22864558
    [No Abstract]   [Full Text] [Related]  

  • 12. Tumour necrosis factor-α antagonists in patients with concurrent psoriasis and hepatitis B or hepatitis C: a retrospective analysis of 17 patients.
    Prignano F; Ricceri F; Pescitelli L; Zanieri F; Lotti T
    Br J Dermatol; 2011 Mar; 164(3):645-7. PubMed ID: 21375517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benefit-risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis.
    Langley RG; Strober BE; Gu Y; Rozzo SJ; Okun MM
    Br J Dermatol; 2010 Jun; 162(6):1349-58. PubMed ID: 20394634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [European and British recommendations on the role of biologic interventions in moderate to severe psoriasis].
    Bachelez H; Battistella M
    Ann Dermatol Venereol; 2011 Apr; 138(2 Suppl 2):H14-7. PubMed ID: 21703457
    [No Abstract]   [Full Text] [Related]  

  • 15. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
    Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
    Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mean platelet volume variation after biologic therapy in psoriasis and psoriatic arthritis.
    Capo A; Di Nicola M; Auriemma M; Piaserico S; Cuccurullo C; Santilli F; Davi G; Amerio P
    Eur J Dermatol; 2014; 24(1):133-5. PubMed ID: 24589526
    [No Abstract]   [Full Text] [Related]  

  • 17. Viewpoint on handling anti-TNF failure in psoriasis.
    Bracke S; Lambert J
    Arch Dermatol Res; 2013 Dec; 305(10):945-50. PubMed ID: 24096701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of nail psoriasis with tumor necrosis factor-alpha blocker agents: an open-label, unblinded, comparative study.
    Ozmen I; Erbil AH; Koc E; Tunca M
    J Dermatol; 2013 Sep; 40(9):755-6. PubMed ID: 23834032
    [No Abstract]   [Full Text] [Related]  

  • 19. Sustained efficacy and safety of adalimumab in psoriasis treatment: a retrospective study of 49 patients with and without a history of TNF-alpha antagonist treatment.
    Van L; Modi SV; Yang DJ; Hsu S
    Arch Dermatol; 2008 Jun; 144(6):804-6. PubMed ID: 18559778
    [No Abstract]   [Full Text] [Related]  

  • 20. Pustular psoriasis following treatment of rheumatoid arthritis with TNF-alpha inhibitors.
    Egnatios G; Warthan MM; Pariser R; Hood AF
    J Drugs Dermatol; 2008 Oct; 7(10):975-7. PubMed ID: 19112764
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.